Do you recall earlier this year when the stock flatlined around $1.50 for weeks and then suddenly traded up to nearly $3? That was my best trade of the year, and I did it again on a smaller scale when it pulled back into the $1.80s and then took off for $3 again. You know it could do it again if that 12 city trial comes in looking better than the Denver study. Almost all small-cap bios are pulling back a lot right now.